The LILAC -TIMI 76 trial (ClinicalTrials.gov ID No. NCT05712200) is an ongoing randomized, double blind phase 3 trial investigating the efficacy and safety of the FXI inhibitor abelacimab, given subcutaneously once a month, compared to placebo in ~ 1,900 patients with AF deemed unsuitable for anticoagulation, which is still recruiting. Here, F11 is linked to atrial fibrillation.